small molecule drug discovery

Altay Therapeutics is a drug discovery company unlocking the therapeutic potential of transcription factor inhibition to address serious, underserved diseases. Its pipeline includes the first oral small molecule inhibitor of DUX4 for facioscapulohumeral muscular dystrophy (FSHD) and a potential best-in-class STAT3 inhibitor with broad potential in cancer and chronic inflammatory diseases. The company has developed a therapeutic area-agnostic drug discovery platform identifying novel allosteric sites to design highly-selective small molecule inhibitors.

allosteric site identificationsmall molecule inhibitor designtranscription factor inhibition

Avantyx LLC is a women-owned startup company developing a therapeutic agent to prevent and restore peripheral nerve damage caused by chemotherapy and diabetes. Its research team identified a unique mechanism causing peripheral nerve damage and is working on a therapeutic drug targeting the root cause of neuropathy to prevent nerve damage and restore nerve function.

drug discoveryperipheral neuropathy research

BioVersys is an award-winning Swiss pharmaceutical company headquartered in Basel, Switzerland, focused on research and development of small molecules that work by novel modes of action and against novel targets to fight bacterial infections and antimicrobial resistance (AMR). Its pipeline includes BV100, Alpibectir, BV200, BV500 and discovery programs targeting serious hospital infections, MDR-TB, TB meningitis, S. aureus and NTM infections.

clinical developmentCMC strategy and operationspreclinical developmentresearch and development

Blacksmith Medicines is a biotechnology company based in San Diego, California, focused on the discovery and development of small molecule inhibitors of metal-dependent enzymes (metalloenzyme-targeted medicines) using a purpose-built platform. The company describes itself as honoring the tradition of blacksmiths through hard-work and invention in modern medicine.

metalloenzyme inhibitor development

BridGene Biosciences is a biotechnology company pioneering next-generation chemoproteomics with its IMTAC™ platform to discover small molecule drugs for undruggable targets in oncology, neurology, and immunology.

chemoproteomics

Camino Pharma is a San Diego-based startup company focused on discovering and developing first-in-class therapies for patients suffering from cancer and CNS disorders. They target signaling proteins based on emerging biological concepts and discover novel mechanisms for modulating these targets with small molecule drugs.

drug developmentdrug discoverytarget biology

Chemestmed is an Estonian biotech company developing first-in-class drugs to treat CNS and metabolic diseases and disorders. It works in epitranscriptomics, developing a technological platform for discovery of novel drugs based on mRNA regulation in cells, including small-molecule activators targeting the METTL3/METTL14 methyltransferase complex to enhance RNA m⁶A methylation.

cell-based assay developmentCRISPR/Cas9 gene editingenzyme assaysepitranscriptomics researchin vitro cell culturemolecular modelingNMR analysisorganic synthesisquantum chemistry calculationsvirtual screening

Cogent Biosciences is a biotechnology company developing precision therapies for genetically driven diseases. It focuses on rational precision therapies leveraging validated biology to address underlying drivers of disease, with a discovery organization in Boulder, Colorado pioneering small molecule therapeutics. Its lead therapy is bezuclastinib, being developed for systemic mastocytosis and GIST.

clinical developmentDrug commercialization

Cognitive Synergy Corporation is a biotechnology company developing novel small-molecule therapies for Alzheimer's disease and related neurodegenerative disorders. Its lead candidate is designed to restore synaptic health while reducing amyloid and tau pathology, aiming to be a disease-modifying treatment. The company integrates translational biomarkers, pharmacology, and behavioral outcomes and is progressing its small molecule through IND-enabling studies toward early clinical trials.

IND-enabling studiespharmacologypreclinical researchtranslational biomarkers

ConquestBio is a Drug Discovery and Development company registered in Delaware with operations in Florida. It applies structural biology, computational biology, AI, ML and GenAI to design and discover safe and efficacious small molecule drugs at scale, focusing on biologically and clinically validated molecular targets. Its GenAI-driven platform integrates biology and pharmacology to design drugs that inhibit protein-protein interactions driving serious diseases.

AI-based drug designcomputational biologyGenAI modelingmachine learningstructural biology

TRANSFORMING THE DRUG DISCOVERY PROCESS With our decades’ worth of drug discovery expertise and breakthrough computationalplatform, we are setting the pace for the next generation of drug discovery. No Guesses, Just Successes by Computational Design Learn More About Our Platform Denovicon’s mission is to bring better quality drugs to market faster and more affordably than existing methods. To do so, we’ve created a drug discovery platform that’s powered by AI, machine learning, generative therapeutic design, and physics-based approaches to achieve the best results. The platform effectively and swiftly triages trillions of molecules to identify high-quality leads (not simply hits) and transform them into optimized clinical candidates. In this way, the platform streamlines the overall drug discovery process leading to savings in time and money, while achieving higher rates of clinical.

AI/machine learning drug discoverycomputational designgenerative therapeutic designmulti-objective optimizationphysics-based modeling

Eradivir is a clinical-stage biotechnology company founded in March 2020 by Dr. Philip S. Low and Martin Low, based in West Lafayette, Indiana. It develops small molecules using its Bispecific Antigenic immuno-Therapy (BAiT) technology that target diseased cells and viruses, flagging them for clearance by the immune system. The company is developing therapies for influenza, RSV, and other serious diseases, including EV25 for influenza.

clinical developmentmedicinal chemistrypreclinical developmentvirology research

iOnctura is a clinical-stage biotechnology company developing precision medicines for cancer and other challenging diseases. Founded in 2017, it develops high impact, low disruption therapies targeting the tumor-stroma-immune interface, focusing on neglected and hard to treat cancers with more effective, less toxic treatments.

clinical developmentdrug developmentoncology research

Kayothera, Inc. is a preclinical therapeutics company developing first-in-class, orally-available small molecule inhibitors of the retinoid and rexinoid nuclear receptor pathways. Its approach blocks the formation of retinoid or rexinoid nuclear ligands, targeting pathways that drive cardiometabolic and cancer outcomes. The company is developing medicines for diabetes, obesity and other unmet medical needs, and has nominated KAYO-1732 as a development candidate for type 2 diabetes and cardiometabolic indications.

preclinical therapeutics development